GAPS IN VACCINE SUPPLY

Between the Serum Institute of India, Bharat Biotech and Biological E Ltd, India has the capacity to manufacture 3 billion doses of vaccines of any kind in a year. But export commitments, late approvals and slow manufacturing have meant the country has seen only 110 million doses in 3 months

Manufactured by Serum Institute of India

Capacity to manufacture

70-100 million doses of Covishield per month; 1.3-1.5 billion doses of other vaccines annually

Vials given to India

100 million; new order for another 100 million placed in March-end

Price paid for each vial Rs 210; new order for Rs 150

Revenue generated

Projected revenue of $4 billion (around Rs 30,052 crore) in two years from its Covid vaccines; the company recorded sales worth $250 million (around Rs 1,878 crore) in the past three months by supplying 70 million doses to over 80 countries Export commitments ➘ SII has committed 200 million doses to Gavi the Vaccine Alliance and Bill & Melinda Gates Foundation at Rs 250 per dose ➘ AstraZeneca’s sublicensing agreement with the SII is to supply up to 1 billion doses of the vaccine to low- and middleincome countries

Manufacturing plans

Chairman Adar Poonawalla recently announced production in India to be “very stressed” and said he will need Rs 3,000 crore to scale up production

Efficacy 59.9% (depending on India’s dosing interval)

No. of doses administered in India 97,318,156